Treatment of inflammatory bowel disease patients with anti-TNF-α factors and immunosuppressives does not influence the prevalence of Helicobacter pylori infection

Indian Journal of Gastroenterology

Volumn 33, Issue 4, 2014, Pages 383-384

  Triantafillidis, John K ^a   Gikas, Aristofanis ^b   Merikas, Emmanuel ^a  

^a Saint Panteleimon General Hospital   (Greece)

^b Health Center of Kalivia   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84883462089     PISSN: 02548860     EISSN: 09750711     Source Type: Journal    
DOI: 10.1007/s12664-013-0389-z     Document Type: Letter

References (6)

1. Luther J, Dave M, Higgins PD, et al. Association between Helicobacter pylori infection and inflammatory bowel disease: a meta-analysis and systematic review of the literature. Inflamm Bowel Dis. 2010;16:1077–84.
2. Zhang S, Zhong B, Chao K, et al. Role of Helicobacter species in Chinese patients with inflammatory bowel disease. J Clin Microbiol. 2011;49:1987–9.
3. Triantafillidis JK, Gikas A, Apostolidis N, et al. The low prevalence of Helicobacter pylori infection in patients with inflammatory bowel disease could be attributed to previous antibiotic treatment. Am J Gastroenterol. 2003;99:1213–4.
4. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;2:CD008794.
5. Beales IL, Calam J. Helicobacter pylori infection and tumour necrosis factor-alpha increase gastrin release from human gastric antral fragments. Eur J Gastroenterol Hepatol. 1997;9:773–7.
6. Hopman WP, de Jong DJ, Naber AH, et al. Tumour necrosis factor alpha antibody affects gastrin release in Crohn disease. Scand J Gastroenterol. 2003;38:522–5.